Akums Drugs & Pharma

AKUMS

NSE

BSE

SectorHealthcare

Loading chart…

Company insights, generated from the most recent coverage.

Moderate medium-term risk (2-4 years) mitigated by strong customer relationships (1,500+ customers, 15+ year avg tenure) and financial flexibility (₹1,600 Cr cash) for strategic acquisitions.
Read more
Management holds ₹1,600 Cr cash for strategic acquisitions, signaling continued inorganic growth strategy beyond this deal.
Read more
₹56 Cr Oriflame acquisition adds skincare, color cosmetics, and wellness manufacturing capabilities, expanding addressable market to $21B India BPC sector (10-11% CAGR) and $92.6B global color cosmetics market.
Read more

The Quarter story

The two most recent quarterly results, compared side-by-side.

CDMO growth fuels profit recovery as formulation margins face headwinds

CDMO revenue grew from ₹813 Cr in Q1 FY26 to ₹964 Cr in Q1 FY27, driving the company's core expansion

Domestic branded formulation EBITDA margin fell from 21.7% in Q4 FY26 to 10.3% in Q1 FY27, signaling cost pressures

Consolidated PAT expanded from ₹43 Cr in Q2 FY26 to ₹101 Cr in Q1 FY27, confirming strong profit recovery

International branded formulation EBITDA margin dropped from 28.0% in Q4 FY26 to 19.9% in Q1 FY27, indicating margin compression

Gross profit margin improved from 41.5% in Q3 FY26 to 44.7% in Q1 FY27, reflecting better cost control

Trade generics revenue declined from ₹27 Cr in Q4 FY26 to ₹21 Cr in Q1 FY27, showing segment contraction

Total income climbed from ₹1,050 Cr in Q2 FY26 to ₹1,197 Cr in Q1 FY27, maintaining steady top-line growth

API EBITDA remained negative, moving from -₹12 Cr in Q4 FY26 to -₹4 Cr in Q1 FY27, with revenue shrinking to ₹32 Cr

Borrowing repayment utilization held at ₹159.91 Cr from Q1 FY26 to Q1 FY27, showing disciplined debt reduction

Employee expenses rose from ₹189 Cr in Q2 FY26 to ₹201 Cr in Q1 FY27, reflecting steady headcount growth

About the company

Akums Drugs and Pharmaceuticals Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) established in 2004. The company offers a wide range of pharmaceutical products and services both domestically and internationally. Their operations include manufacturing of Active Pharmaceutical Ingredients (APIs), sale of branded pharmaceutical formulations, formulation research and development, regulatory dossier preparation and filing, and testing services. Akums has manufacturing units accredited by global regulatory agencies and specializes in various therapeutic areas. The company has expanded through acquisitions and establishment of new facilities over the years. It operates in three main segments: CDMO, API, and Branded and Generic formulations. Akums has manufactured over 4,000 commercialized formulations across more than 60 dosage forms.

In the news

CDMO Showdown: Gland, Akums, and Kwality—Three Paths to Growth

5 stocks show 28% upside potential as Q1 FY27 earnings approach

Akums Drugs & Pharma

Insights

About the company

Insights